Feig LA - Search Results

1

Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Lim KH, et al. Among authors: feig la. Cancer Cell. 2005 Jun;7(6):533-45. doi: 10.1016/j.ccr.2005.04.030. Cancer Cell. 2005. PMID: 15950903 Free article.

2

RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells.

Shipitsin M, Feig LA. Shipitsin M, et al. Among authors: feig la. Mol Cell Biol. 2004 Jul;24(13):5746-56. doi: 10.1128/MCB.24.13.5746-5756.2004. Mol Cell Biol. 2004. PMID: 15199131 Free PMC article.

3

Ral-GTPase influences the regulation of the readily releasable pool of synaptic vesicles.

Polzin A, Shipitsin M, Goi T, Feig LA, Turner TJ. Polzin A, et al. Among authors: feig la. Mol Cell Biol. 2002 Mar;22(6):1714-22. doi: 10.1128/MCB.22.6.1714-1722.2002. Mol Cell Biol. 2002. PMID: 11865051 Free PMC article.

4

An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity.

Goi T, Shipitsin M, Lu Z, Foster DA, Klinz SG, Feig LA. Goi T, et al. Among authors: feig la. EMBO J. 2000 Feb 15;19(4):623-30. doi: 10.1093/emboj/19.4.623. EMBO J. 2000. PMID: 10675331 Free PMC article.

5

RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.

Ladeda V, Frankel P, Feig LA, Foster DA, Bal de Kier Joffe E, Aguirre-Ghiso JA. Ladeda V, et al. Among authors: feig la. Biochem Biophys Res Commun. 2001 May 18;283(4):854-61. doi: 10.1006/bbrc.2001.4845. Biochem Biophys Res Commun. 2001. PMID: 11350063

6

The chemotactic response to PDGF-BB: evidence of a role for Ras.

Kundra V, Anand-Apte B, Feig LA, Zetter BR. Kundra V, et al. Among authors: feig la. J Cell Biol. 1995 Aug;130(3):725-31. doi: 10.1083/jcb.130.3.725. J Cell Biol. 1995. PMID: 7622571 Free PMC article.

7

RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin.

Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA. Sowalsky AG, et al. Among authors: feig la. Cancer Res. 2011 Feb 1;71(3):758-67. doi: 10.1158/0008-5472.CAN-10-2756. Epub 2010 Dec 15. Cancer Res. 2011. PMID: 21159665 Free PMC article.

8

RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.

Aguirre-Ghiso JA, Frankel P, Farias EF, Lu Z, Jiang H, Olsen A, Feig LA, de Kier Joffe EB, Foster DA. Aguirre-Ghiso JA, et al. Among authors: feig la. Oncogene. 1999 Aug 19;18(33):4718-25. doi: 10.1038/sj.onc.1202850. Oncogene. 1999. PMID: 10467419

9

Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain.

Farnsworth CL, Marshall MS, Gibbs JB, Stacey DW, Feig LA. Farnsworth CL, et al. Among authors: feig la. Cell. 1991 Feb 8;64(3):625-33. doi: 10.1016/0092-8674(91)90246-u. Cell. 1991. PMID: 1899358

10

RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.

Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA. Sowalsky AG, et al. Among authors: feig la. Oncogene. 2010 Jan 7;29(1):45-55. doi: 10.1038/onc.2009.307. Epub 2009 Oct 5. Oncogene. 2010. PMID: 19802010 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters